- Home
- AXL vs EOLS Comparison
AXL vs EOLS Comparison
Compare AXL & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- EOLS
- Stock Information
- Founded
- AXL 1994
- EOLS 2012
- Country
- AXL United States
- EOLS United States
- Employees
- AXL N/A
- EOLS N/A
- Industry
- AXL Auto Parts:O.E.M.
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- AXL Consumer Discretionary
- EOLS Health Care
- Exchange
- AXL Nasdaq
- EOLS Nasdaq
- Market Cap
- AXL 739.6M
- EOLS 702.2M
- IPO Year
- AXL 1999
- EOLS 2018
- Fundamental
- Price
- AXL $5.90
- EOLS $10.51
- Analyst Decision
- AXL Hold
- EOLS Strong Buy
- Analyst Count
- AXL 4
- EOLS 6
- Target Price
- AXL $7.38
- EOLS $22.60
- AVG Volume (30 Days)
- AXL 1.7M
- EOLS 695.8K
- Earning Date
- AXL 02-14-2025
- EOLS 03-06-2025
- Dividend Yield
- AXL N/A
- EOLS N/A
- EPS Growth
- AXL N/A
- EOLS N/A
- EPS
- AXL 0.23
- EOLS N/A
- Revenue
- AXL $6,207,100,000.00
- EOLS $248,326,000.00
- Revenue This Year
- AXL $1.78
- EOLS $33.43
- Revenue Next Year
- AXL N/A
- EOLS $32.44
- P/E Ratio
- AXL $25.42
- EOLS N/A
- Revenue Growth
- AXL 3.29
- EOLS 34.42
- 52 Week Low
- AXL $5.41
- EOLS $9.25
- 52 Week High
- AXL $8.98
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- AXL 47.70
- EOLS 42.77
- Support Level
- AXL $5.82
- EOLS $9.25
- Resistance Level
- AXL $6.10
- EOLS $11.66
- Average True Range (ATR)
- AXL 0.20
- EOLS 0.55
- MACD
- AXL 0.04
- EOLS 0.06
- Stochastic Oscillator
- AXL 71.00
- EOLS 52.28
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.